{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.3","upperLimit":"25.0","value":"5.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"}],"units":"Participants"}],"description":"VGPR or better response rate was defined as the percentage of participants who achieved VGPR or better according to the modified sixth IWWM (NCCN 2019) criteria as assessed by the investigator. VGPR: \\>=90% reduction of serum IgM from baseline or normal serum IgM values, with reduction in lymphadenopathy/splenomegaly if present at baseline.","dispersionType":"90% Confidence Interval","groups":[{"description":"Participants with relapsed or refractory waldenstrom's macroglobulinemia received ibrutinib 420 milligrams (mg) (3\\*140 mg capsules) orally once daily from Day 1 of Week 1 until disease progression, unacceptable toxicity, whichever occurs first.","id":"OG000","title":"Ibrutinib 420 mg"}],"paramType":"NUMBER","populationDescription":"All treated analysis set included all enrolled participants who received at least 1 dose of study drug.","reportingStatus":"POSTED","timeFrame":"From start of the treatment (Day 1) up to 49.3 months","title":"Very Good Partial Response (VGPR) or Better Response Rate","type":"SECONDARY","unitOfMeasure":"Percentage of Participants"}